Afsaneh Alavi, Dermatology Meeting News 2022: Phase 2 Trial of Vilobelimab for Ulcerative Pyoderma Gangrenosum
Vilobelimab is an anti-C5a antibody currently being investigated in the treamtent of ulcerative pyoderma gangrenosum. Dr. Afsaneh Alavi (Mayo Clinic, Rochester, MN, USA) kindly met with touchIMMUNOLOGY to discuss the unmet needs, the rationale for the use of vilobelimab in the treamtent of ulcerative pyoderma gangrenosum and the findings from the phase 2 study.
The abstract ‘Anti-C5a antibody Vilobelimab (IFX-1) treatment in patients with ulcerative pyoderma gangrenosum: Phase 2, open-label dose escalation trial’ was presented at AAD-VMX 2022, 25-29 March.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
- What are the unmet needs in the treatment of ulcerative pyoderma gangrenosum? (0:12)
- What is the rationale for the use of vilobelimab in the treatment of patients with ulcerative pyoderma gangrenosum? (1:52)
- What is the mechanism of action of vilobelimab? (3:29)
- What are the aims, design and inclusion criteria of the phase 2, open-label dose escalation trial? (4:17)
- What were the main outcome measures and how well were these achieved? (5:26)
Disclosures: Afsaneh Alavi discloses consulting for Abbvie, BI, InflaRx, Novartix and UCB; serving on advisory boards for Abbvie, BI, InflaRx, Novartix and UCB; and receiving honoraria from Abbvie, BI, InflaRx, Novartix and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.
Share this Video
Related Videos In Dermatological Conditions
Melinda Gooderham, Dermatology Meeting News 2023: Abrocitinib efficacy in atopic dermatitis by baseline disease severity – findings from an interim analysis of JADE EXTEND
JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of JADE-EXTEND, looking at efficacy by baseline disease severity. The abstract ‘Influence of Baseline Disease […]
Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis
Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor approved for the treatment of moderate to severe plaque psoriasis, a post-hoc analysis of the phase 3 POETYK PSO-1 and PSO-2 trials investigated the efficacy of deucravacitinib by baseline characteristics in this indication. touchIMMUNOLOGY were delighted to speak with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, […]
William Damsky, Dermatology Meeting News 2023: A personalised approach to treating inflammatory skin diseases
Personalised medicine utilises biomarkers to predict patient outcomes and responses to treatment, ensuring that patients get the most effective treatment quicker. We were delighted to speak to Expert Faculty member Dr. William Damsky (Yale School of Medicine, New Haven, CT, USA) around the recent advances made in biomarkers and targeted therapies for inflammatory skin diseases, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!